• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams.

    Schedule 1x1 meetings here.

    "This week's Life Sciences Virtual Investor Forum brings together a compelling roster of innovators from across the sector," said Greg Young, AVP, Investor Access, OTC Markets. "Our Virtual Investor Conferences continue to provide an efficient platform for these companies to engage directly with investors and communicate their strategies."

    June 24th

    Presentation

    Time (ET)
    CompanyTicker(s)
    10:30 AM ETMetaVia Inc.(NASDAQ:MTVA)
    11:00 AM ETNasus Pharma Ltd.(NYSE:NSRX)
    11:30 AM ETCytoSorbents Corporation(NASDAQ:CTSO)
    12:00 PM ETPetVivo Holdings Inc.(OTCQX:PETV)
    1:00 PM ETJaguar Health, Inc.(NASDAQ:JAGX)
    1:30 PM ETReviva Pharmaceuticals Holdings, Inc.(OTCQB:RVPH)
    2:00 PM ETZivo Bioscience, Inc.(OTCID: ZIVO)
    3:00 PM ET4DMedical Limited(OTC:FDMDF, ASX: 4DX))



    June 25th

    Presentation

    Time (ET)
    CompanyTicker(s)
    9:30 AM ETProstatype Genomics AB(OTCQB:PGABF, NASDAQ Stockholm: PROGEN))
    10:00 AM ETAbingdon Health plc(OTCQB:ABDXF, LSE: ABDX))
    10:30 AM ETInnovotech, Inc.(OTCQB:IOTCF, TSXV:IOT)
    11:00 AM ETLakewood-Amedex Biotherapeutics Inc.(NASDAQ:LABT)
    11:30 AM ETKelyniam Global, Inc.(OTCID: KLYG)
    12:00 PM ETIMUNON, Inc.(NASDAQ:IMNN)
    12:30 PM ETPromino Nutritional Sciences Inc.((OTCID: MUSLF, CSE:MUSL)
    1:00 PM ETEnvoy Medical Inc.(NASDAQ:COCH)
    1:30 PM ETCoiled Therapeutics plc(OTCQB:COTXF, AIM: COIL))
    2:00 PM ETAspire Biopharma Holdings Inc.(NASDAQ:ASBP)
    2:30 PM ETRocket Doctor AI Inc.(OTCQB:AIRDF, CSE:AIDR)
    3:00 PM ETPhio Pharmaceuticals Corp.(NASDAQ:PHIO)
    3:30 PM ETaTyr Pharma, Inc.(NASDAQ:ATYR)
    4:00 PM ETNuFarm Ltd.(OTC:NUFMF, ASX: NUF))

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

    Virtual Investor Conferences Contact:

    Greg Young


    VP Corporate Services


    OTC Markets Group


    (212) 652-5958


    greg@otcmarkets.com



    Primary Logo

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA
    $NSRX
    $CTSO
    $PETV

    CompanyDatePrice TargetRatingAnalyst
    Envoy Medical Inc.
    $COCH
    3/31/2026$2.50Buy
    H.C. Wainwright
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    aTyr Pharma Inc.
    $ATYR
    9/16/2025$1.50Outperform → Sector Perform
    RBC Capital Mkts
    aTyr Pharma Inc.
    $ATYR
    9/15/2025$1.00Overweight → Equal Weight
    Wells Fargo
    aTyr Pharma Inc.
    $ATYR
    9/15/2025Buy → Neutral
    H.C. Wainwright
    aTyr Pharma Inc.
    $ATYR
    9/15/2025$1.00Outperform → Market Perform
    Leerink Partners
    aTyr Pharma Inc.
    $ATYR
    9/15/2025Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    6/22/26 7:12:42 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mariani Peter J bought $44,000 worth of shares (100,000 units at $0.44), increasing direct ownership by 19% to 638,113 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    6/16/26 7:00:14 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Chan Phillip P. bought $104,898 worth of shares (261,469 units at $0.40), increasing direct ownership by 18% to 1,744,432 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    6/15/26 6:24:29 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Reviva Pharmaceuticals with a new price target

    Chardan Capital Markets initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $2.00

    9/29/25 9:59:06 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

    CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD., Founder, President and CEO, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 24th, 2026. DATE: June 24th TIME: 1:30 PM ET REGISTER HERE Reviva Management is available for 1x1 meetings: June 26 and June 30. To schedule 1x1 Meetings, please click here The event will be conducted

    6/23/26 8:00:00 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

    On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating unprecedented IL-12 safety profile and extraordinary Phase 2 efficacy LAWRENCEVILLE, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoa

    6/23/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman of Board Tardugno Michael H was granted 4,629 shares, increasing direct ownership by 36% to 17,467 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/23/26 7:59:08 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Lucas Brent T.

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/23/26 6:28:40 PM ET
    $COCH
    Industrial Specialties
    Health Care

    President and CEO Lindborg Stacy was granted 1,803 shares, increasing direct ownership by 34% to 7,038 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/23/26 4:17:54 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    SEC Filings

    View All

    Aspire Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

    6/22/26 4:35:33 PM ET
    $ASBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Jaguar Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K/A - Jaguar Health, Inc. (0001585608) (Filer)

    6/22/26 4:25:36 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.

    424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

    6/22/26 4:11:56 PM ET
    $LABT

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Financials

    Live finance-specific insights

    View All

    CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

    PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlights, and provides a regulatory update.  CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbent

    5/13/26 4:00:00 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

    IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported fin

    5/12/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

    Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.Management to host conference call and webcast today at 4:30pm ET / 1:30pm PT. SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced th

    5/11/26 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET. This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast wi

    6/17/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

    POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors, effective as of June 5, 2026. In connection with their appointment to the Board of Directors, Mr. Sonenreich has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Committee, Ms. Hannaway has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Commit

    6/9/26 7:00:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

    Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance

    4/28/26 7:33:00 AM ET
    $ENVB
    $LABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    $NSRX
    $CTSO
    $PETV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by aTyr Pharma Inc.

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    11/14/24 6:51:17 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care